ISSN ONLINE: 2558-815X
ISSN PRINT: 1584-9244
ISSN-L: 1584-9244

Maximum Benefit From the Addition of Ezetimibe to Statin Therapy Is Seen in Patients With Diabetes


The IMPROVE-IT trial showed that Ezetimibe was the first non-statin agent which reduced major cardiovascular events in combination with a statin. 18,144 patients with an LDL-C level of 50 to 125 mg/dL were randomized to receive ezetimibe plus simvastatin 40 mg or placebo plus simvastatin 40 mg (P/S) to compare benefits in those with and without diabetes mellitus. Adding ezetimibe to statin therapy provided maximum clinical benefit for patients with DM or those at a high cardiovascular risk.



Comments are closed.